<img alt="" src="https://secure.hiss3lark.com/178938.png" style="display:none;" />

Get Involved

Help make a difference in the lives of those with autoimmune disease.

What is Autoimmune Disease?
- AUTOIMMUNE VS AUTOINFLAMMATORY DISEASE
  
  A Comparative Look
  
  Autoimmune disease (AD) and autoinflammatory disease (AIF) are two categories of illnesses that occur when the immune system mistakenly damages healthy cells. Although these inflammatory disorders share many commonalities, there are key features that make them unique.
  Read Our Article
  Autoimmune diseases (AD) occur when the immune system attacks the body’s own healthy cells. There are 80-100 known autoimmune diseases and counting, affecting more than 14 million Americans.
  AUTOIMMUNE VS AUTOINFLAMMATORY DISEASE
  
  A Comparative Look
  
  Autoimmune disease (AD) and autoinflammatory disease (AIF) are two categories of illnesses that occur when the immune system mistakenly damages healthy cells. Although these inflammatory disorders share many commonalities, there are key features that make them unique.
  
  Read Our Article
Resources & Support
- FREE RESOURCE
  
  Find Hope in Your Health Journey
  
  The Autoimmune & Chronic Illness Toolkit includes journal templates, resource lists, guidance for doctor appointments, tips on communication, and many more tools to support and empower you throughout your experience.
  Get Our Guide
  Browse our resource lists and information via the links below.
  FREE RESOURCE
  
  Find Hope in Your Health Journey
  
  The Autoimmune & Chronic Illness Toolkit includes journal templates, resource lists, guidance for doctor appointments, tips on communication, and many more tools to support and empower you throughout your experience.
  
  Get Our Guide
Education & Research
- HIGHLIGHTED PARTNERSHIP
  
  GAI is proud to fund the Raising Celiac podcast from the Celiac Disease Program at Boston Children’s Hospital
  
  Each episode features education, awareness and research on celiac disease in connection with other autoimmune conditions, including expert interviews on how these autoimmune diseases co-exist.
  View Podcast
  We support autoimmune disease research, awareness, and education. We fund clinical research, scientific investigations, multidisciplinary medicine, and educational resources, including podcasts and webinars.
  HIGHLIGHTED PARTNERSHIP
  
  GAI is proud to fund the Raising Celiac podcast from the Celiac Disease Program at Boston Children’s Hospital
  
  Each episode features education, awareness and research on celiac disease in connection with other autoimmune conditions, including expert interviews on how these autoimmune diseases co-exist.
  
  View Podcast
About Us
- SPREADING AWARENESS
  
  We were proud to sponsor Nature Magazine’s July 2021 Outlook on Autoimmune Disease
  
  Learn more about GAI's work, autoimmune risk factors, research advances, and more!
  Read Our Feature
  The Global Autoimmune Institute is empowering solutions in the diagnosis and treatment of autoimmune disease (AD) through research, education, and validation while supporting multidisciplinary approaches to wellness.
  SPREADING AWARENESS
  
  We were proud to sponsor Nature Magazine’s July 2021 Outlook on Autoimmune Disease
  
  Learn more about GAI’s work, autoimmune risk factors, research advances, and more!
  
  Read Our Feature
Search

The Effect of Anti-CD20 Therapies on SARS-CoV-2 Immune Responses in Multiple Sclerosis Patients

August 11, 2021

Researchers in France investigated the humoral immune response to COVID-19 in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMO-SD). Humoral immune responses use antibodies to protect against reinfection when exposed to a foreign invader.

The results of the study showed a high seroconversion rate in patients with MS and NMO-SD after COVID-19. However, patients treated with anti-CD20 therapies had a seroconversion rate twice as low as untreated patients and patients receiving a different treatment. In other words, patients treated with anti-CD20 therapies exhibited a weaker antibody response against a COVID-19 infection. Some factors found to influence seroconversion rates included IgG levels and severity of COVID-19 infection. The time between the last anti-CD20 infusion and COVID-19 was also longer in seropositive patients.

« Antibody Development Following COVID Vaccine in Autoimmune Disease Patients

Using Infliximab to Treat COVID »